IFNAR1: Cytokine Receptor and Signaling Protein (G3454)

Target Name: IFNAR1

NCBI ID: G3454

IFNAR1

IFNAR1: Cytokine Receptor and Signaling Protein

IFNAR1 (cytokine receptor family 2 member 1) is a protein that is expressed in various tissues throughout the body, including the liver, pancreas, and blood cells. It is a member of the IFNAR family, which is a subgroup of the cytokine receptor family. IFNAR1 is involved in the signaling process of cytokines, which are a group of small signaling proteins that are involved in various physiological processes in the body.

IFNAR1 is a transmembrane protein that is composed of an extracellular domain, a transmembrane region, and an intracellular domain. The extracellular domain of IFNAR1 is involved in the formation of a complex with other proteins, which allows it to interact with cytokines. The transmembrane region of IFNAR1 is responsible for the protein's ability to interact with cytokines and other molecules. The intracellular domain of IFNAR1 is responsible for the protein's ability to interact with the cytoskeleton and other intracellular structures.

IFNAR1 is involved in the regulation of a wide range of physiological processes in the body, including inflammation, immune response, and cell signaling. It is part of a signaling pathway that is involved in the regulation of cytokine signaling, which is the process by which cytokines are produced and released in response to the presence of certain molecules in the body.

IFNAR1 is a potential drug target for a variety of diseases, including cancer, autoimmune disorders, and cardiovascular disease. It is also a potential biomarker for these diseases, as its levels may be affected by the presence of certain cytokines. For example, high levels of IFNAR1 may be associated with the development of cancer, and reducing IFNAR1 levels may be a potential treatment for this disease. Similarly, high levels of IFNAR1 may be associated with the development of autoimmune disorders, and reducing IFNAR1 levels may be a potential treatment for these disorders.

IFNAR1 is also involved in the regulation of cellular signaling pathways that are important for the growth, differentiation, and survival of various cell types. It is part of a signaling pathway that is involved in the regulation of cell proliferation, migration, and apoptosis. This pathway is important for the development and maintenance of tissues and organs, and dysregulation of this pathway has been implicated in the development of a wide range of diseases, including cancer.

IFNAR1 is also involved in the regulation of the immune system, which is responsible for protecting the body against the presence of foreign substances and ensuring that it is able to fight off infections. It is part of a signaling pathway that is involved in the regulation of T cell development and function, which are important for the immune response. IFNAR1 plays a role in the regulation of this pathway by interacting with cytokines, which are involved in the immune response.

IFNAR1 is a protein that is involved in a wide range of physiological processes in the body. It is a potential drug target for a variety of diseases, including cancer, autoimmune disorders, and cardiovascular disease, and is also a potential biomarker for these diseases. Further research is needed to fully understand the role of IFNAR1 in the regulation of these processes and to develop effective treatments for these diseases.

Protein Name: Interferon Alpha And Beta Receptor Subunit 1

Functions: Together with IFNAR2, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa) (PubMed:2153461, PubMed:7813427, PubMed:10049744, PubMed:14532120, PubMed:15337770, PubMed:24075985, PubMed:21854986, PubMed:31270247, PubMed:33252644, PubMed:35442418). Type I interferon binding activates the JAK-STAT signaling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response (PubMed:7665574, PubMed:10049744, PubMed:21854986). Mechanistically, type I interferon-binding brings the IFNAR1 and IFNAR2 subunits into close proximity with one another, driving their associated Janus kinases (JAKs) (TYK2 bound to IFNAR1 and JAK1 bound to IFNAR2) to cross-phosphorylate one another (PubMed:7813427, PubMed:7665574, PubMed:21854986, PubMed:32972995). The activated kinases phosphorylate specific tyrosine residues on the intracellular domains of IFNAR1 and IFNAR2, forming docking sites for the STAT transcription factors (PubMed:7813427, PubMed:7526154, PubMed:7665574, PubMed:21854986, PubMed:32972995). STAT proteins are then phosphorylated by the JAKs, promoting their translocation into the nucleus to regulate expression of interferon-regulated genes (PubMed:7813427, PubMed:7665574, PubMed:9121453, PubMed:19561067, PubMed:21854986, PubMed:32972995). Can also act independently of IFNAR2: form an active IFNB1 receptor by itself and activate a signaling cascade that does not involve activation of the JAK-STAT pathway (By similarity)

The "IFNAR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFNAR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets